Table 4.
Predictors of activity response (activity grades decreasing or maintaining at A0) in non-SVR cases (n = 26) among the entire cohort (n = 85).
| Variable | n | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | ||
| Baseline characteristics | |||||
| PegIFN-α, 2a versus 2b | 16 versus 10 | 1.467 (0.282–7.627) | 0.649 | ||
| Sex, male versus female | 17 versus 9 | 1.920 (0.358–10.286) | 0.446 | ||
| Age, <48 versus ⩾48 | 9 versus 17 | 7.111 (0.723–69.985) | 0.093 | ||
| METAVIR scores | |||||
| Fibrosis stages, <2 versus ⩾2 | 11 versus 15 | 0.208 (0.037–1.181) | 0.076 | ||
| Activity grades, <2 versus ⩾2 | 20 versus 6 | 0.300 (0.029–3.071) | 0.310 | ||
| Steatosis scores, 0 versus ⩾1 | 7 versus 19 | 0.615 (0.104–3.658) | 0.593 | ||
| Alcohol abuse, (–) versus (+) | 21 versus 5 | 1.333 (0.179–9.912) | 0.779 | ||
| Diabetes mellitus, (–) versus (+) | 21 versus 5 | 1.333 (0.179–9.912) | 0.779 | ||
| HCV RNA (106 copies/ml) | |||||
| ⩽2 versus >2 | 5 versus 21 | 0.267 (0.035–2.019) | 0.201 | ||
| ⩽3 versus >3 | 9 versus 17 | 0.521 (0.097–2.790) | 0.446 | ||
| AST (U/l) | |||||
| ⩽40 versus >40 | 8 versus 18 | 0.833 (0.147–4.723) | 0.837 | ||
| ⩽80 versus >80 | 15 versus 11 | 0.563 (0.105–3.023) | 0.502 | ||
| ALT (U/l) | |||||
| ⩽55 versus >55 | 8 versus 18 | 0.385 (0.068–2.164) | 0.278 | ||
| ⩽110 versus >110 | 19 versus 7 | 0.686 (0.104–4.522) | 0.695 | ||
| Total bilirubin (mg/dl), ⩽1.2 versus >1.2 | 19 versus 7 | 0.686 (0.104–4.522) | 0.695 | ||
| Albumin (g/dl), ⩾4.4 versus <4.4 | 10 versus 15 | 1.167 (0.208–6.559) | 0.861 | ||
| Platelet counts (103/µl), ⩾200 versus <200 | 7 versus 19 | 0.268 (0.044–1.640) | 0.154 | ||
| AFP (ng/ml), <4 versus ⩾4 | 10 versus 15 | 1.167 (0.208–6.559) | 0.861 | ||
| Glucose (mg/dl), ⩽105 versus >105 | 16 versus 10 | 16.333 (2.197–121.425) | 0.006* | 17.741 (1.033–304.675) | 0.047* |
| HbA1c (%), <5.7 versus ⩾5.7 | 10 versus 15 | 2.667 (0.414–17.169) | 0.302 | ||
| HDL (mg/dl), ⩾40 versus <40 | 11 versus 12 | 0.583 (0.097–3.506) | 0.556 | ||
| LDL (mg/dl), ⩾135 versus <135 | 4 versus 20 | 1.615 (0.140–18.581) | 0.700 | ||
| Biochemical changes | |||||
| Baseline versus 24 weeks after EOT | |||||
| ALT levels remaining ⩽42 or declining from >42 to ⩽42 U/l, (+) versus (–) | 11 versus 12 | 0.114 (0.016–0.806) | 0.029* | 0.290 (0.014–6.182) | 0.428 |
| Platelet counts remaining ⩾200 103/µl, (+) versus (–) | 5 versus 17 | 0.077 (0.007–0.901) | 0.041* | 0.178 (0.003–10.261) | 0.404 |
| Baseline versus EOS | |||||
| AST levels declining by >30%, (+) versus (–) | 11 versus 15 | 11.429 (1.155–113.115) | 0.037* | 1.516 (0.063–36.591) | 0.798 |
(1) To calculate the OR, each variable was categorized into a binary form with the latter designated as the reference factor. (2) For each variable, cases with missing data were excluded from both univariate and multivariate analysis. (3) Variables entered into multivariate analysis were those showing a p-value <0.05 in univariate analysis. (4) Additional data can be found in Supplementary Tables S8 and S9 online. AFP, alpha-fetoprotein; ALT, alanine transaminase; AST, aspartate transaminase; CI, confidence interval; EOS, end of surveillance; EOT, end of treatment; HbA1c, hemoglobin A1c; HCV, hepatitis C virus; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OR, odds ratio; PegIFN, pegylated interferon; RNA, ribonucleic acid.
Binary logistic regression: A p-value <0.05 was considered statistically significant.
Bold values represent statistical significance in univariate or multivariate analysis.